{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:36:29Z","timestamp":1769513789705,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijtb.2020.06.004","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T00:21:26Z","timestamp":1593822086000},"page":"S147-S154","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S","title":["Hydroxychloroquine and COVID-19 \u2013 A narrative review"],"prefix":"10.1016","volume":"67","author":[{"given":"Jyoti","family":"Bajpai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-7580","authenticated-orcid":false,"given":"Akshyaya","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya","family":"kant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2020.06.004_bib1","series-title":"Coronavirus Disease (COVID-19)- Situation Report 116 : World Health Organization","year":"2020"},{"key":"10.1016\/j.ijtb.2020.06.004_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","author":"Sanders","year":"2020","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ijtb.2020.06.004_bib3","series-title":"Interpretation of COVID-19 Treatment Guidelines (6th Version)","year":"2020"},{"key":"10.1016\/j.ijtb.2020.06.004_bib4","doi-asserted-by":"crossref","first-page":"105945","DOI":"10.1016\/j.ijantimicag.2020.105945","article-title":"Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine","author":"Sahraei","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijtb.2020.06.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198801073180101","article-title":"Treatment of severe chloroquine poisoning","volume":"318","author":"Riou","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2020.06.004_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/archderm.1980.01640290097026","article-title":"Antimalarial agents","volume":"116","author":"Tanenbaum","year":"1980","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijtb.2020.06.004_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","article-title":"Clinical pharmacokinetics and metabolism of chloroquine","volume":"31","author":"Ducharme","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijtb.2020.06.004_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"23","author":"Yan","year":"2013","journal-title":"Cell Res"},{"key":"10.1016\/j.ijtb.2020.06.004_bib9","first-page":"189","article-title":"Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice","volume":"24","author":"Li","year":"2017","journal-title":"Biomedicine"},{"key":"10.1016\/j.ijtb.2020.06.004_bib10","first-page":"267","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.ijtb.2020.06.004_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"issue":"4.23","key":"10.1016\/j.ijtb.2020.06.004_bib12","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijtb.2020.06.004_bib13","series-title":"Regarding Dosage Adjustments to the Experimental Use of Chloroquine Phosphate in the Treatment of COVID-19","year":"2020"},{"key":"10.1016\/j.ijtb.2020.06.004_bib14","unstructured":"Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions against Use outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Drug Safety Communication-FDA.24.04.2020.[Internet] Available form: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use. Accessed: May 15, 2020"},{"key":"10.1016\/j.ijtb.2020.06.004_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In\u00a0vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijtb.2020.06.004_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in\u00a0vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.ijtb.2020.06.004_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and \u2028chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ijtb.2020.06.004_bib18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine Storm' in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.ijtb.2020.06.004_bib19","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"Med Rxiv Prepr Serv Health Sci"},{"key":"10.1016\/j.ijtb.2020.06.004_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijtb.2020.06.004_bib21","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Trav Med Infect Dis"},{"issue":"1","key":"10.1016\/j.ijtb.2020.06.004_bib22","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"Jun","year":"2020","journal-title":"J Zhejiang Univ Med Sci"},{"key":"10.1016\/j.ijtb.2020.06.004_bib23","article-title":"Hydroxy-chloroquine in patients with COVID-19: an open-label, randomized, controlled trial","author":"Tang","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ijtb.2020.06.004_bib24","series-title":"Early Treatment of COVID-19 Patients with Hydroxychloroquine and Azithromycin: A Retrospective Analysis of 1061 Cases in Marseille, France","first-page":"101738","author":"Million","year":"2020"},{"key":"10.1016\/j.ijtb.2020.06.004_bib25","first-page":"369","article-title":"Clinical Efficacy of Hydroxychloroquine in Patients Hospitalized for COVID 19 Infection with Oxygen Requirement: observational comparative study using routine care data","author":"Mahevas","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijtb.2020.06.004_bib26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med Maladies Infect"},{"key":"10.1016\/j.ijtb.2020.06.004_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijtb.2020.06.004_bib28","doi-asserted-by":"crossref","first-page":"286-288","DOI":"10.1097\/RHU.0b013e31829d5e50","article-title":"Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus","volume":"19","author":"Morgan","year":"2013","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.ijtb.2020.06.004_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2020.0148","article-title":"Association of QT prolonging medications with risk of autopsy causes of sudden death","volume":"180","author":"Simpson","year":"2020","journal-title":"JAMA Int Med"},{"issue":"18","key":"10.1016\/j.ijtb.2020.06.004_bib30","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJMp1302726","article-title":"Cardiovascular risks with azithromycin and other antibacterial drugs","volume":"368","author":"Mosholder","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2020.06.004_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","author":"Chorin","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ijtb.2020.06.004_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for COVID-19","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ijtb.2020.06.004_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","author":"Rosenberg","year":"2020","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ijtb.2020.06.004_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients","volume":"6","author":"Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ijtb.2020.06.004_bib35","unstructured":"Indian Council for Medical Research. Recommendation for Empiric Use of Hydroxychloroquine for Prophylaxis of SARS-CoV-2 Infection. Available from: https:\/\/icmr.nic.in\/sites\/default\/files\/upload _ documents\/HCQ_Recommendation_22March_final_MM_V2.pdf.[accessed 30 April 2020]."},{"key":"10.1016\/j.ijtb.2020.06.004_bib36","unstructured":"COVID 19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID 19) Treatment Guidelines. National Institute Of Health Available at: https:\/\/www.covid19treatment.guidelines.nih.gov\/[Accessed 19\/5\/2020]."},{"key":"10.1016\/j.ijtb.2020.06.004_bib37","unstructured":"Wilson KC, Chotirmall SH, Bai C, Rello J. COVID-19: Interim Guidance on Management Pending Empirical Evidence. Last updated April 3, 2020. Available at: www.thoracic.org\/professionals\/clinical-resources\/disease-related-resources\/covid-19-guidance.pdf."},{"issue":"suppl 1","key":"10.1016\/j.ijtb.2020.06.004_bib38","first-page":"S6","article-title":"Indian society of critical care medicine position statement for central venous catheterization and management 2020","volume":"24","author":"Javeri","year":"2020","journal-title":"Indian J Crit Care Med"},{"issue":"3","key":"10.1016\/j.ijtb.2020.06.004_bib39","first-page":"185e8","volume":"43","year":"2020","journal-title":"Zhonghua Jiehe He Huxi Zazhi"},{"key":"10.1016\/j.ijtb.2020.06.004_bib40","unstructured":"http:\/\/www.simit.org\/medias\/1555-covid19-linee-guida-trattamento-01mar. pdf. Last accessed on 19 April 2020."},{"issue":"5","key":"10.1016\/j.ijtb.2020.06.004_bib41","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)","volume":"46","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijtb.2020.06.004_bib42","unstructured":"Solidarity Clinical Trial for COVID-19 treatments. World Health Organization. Available at: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments. [Accessed: May 15, 2020]."}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570720300706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570720300706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T23:59:23Z","timestamp":1607731163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570720300706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0019570720300706"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2020.06.004","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}